AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot
Seeking Alpha News (Sat, 3-Oct 2:37 PM ET)
Scotiabank Keeps Their Buy Rating on Teva (TEVA)
TipRanks (Fri, 2-Oct 8:55 AM ET)
Globe Newswire (Fri, 2-Oct 8:00 AM ET)
Globe Newswire (Fri, 2-Oct 8:00 AM ET)
Piper Sandler Sticks to Its Buy Rating for Teva (TEVA)
TipRanks (Thu, 1-Oct 8:05 AM ET)
Teva and Samsung Bioepis partner on up to six biosimilars
Seeking Alpha News (Thu, 1-Oct 4:54 AM ET)
Globe Newswire (Wed, 30-Sep 4:32 PM ET)
Globe Newswire (Mon, 28-Sep 4:00 PM ET)
Teva Sets Nov. 3 Q3 2026 Results Call, Putting 8:00 a.m. ET on Investors’ Calendars
Market Chameleon (Thu, 24-Sep 4:42 AM ET)
Globe Newswire (Wed, 23-Sep 4:45 PM ET)
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical Industries trades on the NYSE stock market under the symbol TEVA.
As of October 6, 2026, TEVA stock price declined to $39.14 with 2,963,413 million shares trading.
TEVA has a beta of 0.90, meaning it tends to be less sensitive to market movements. TEVA has a correlation of 0.08 to the broad based SPY ETF.
TEVA has a market cap of $45.65 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries reported $4 billion in Revenue and $.02 earnings per share. This beat revenue expectation by $74 million and missed earnings estimates by -$.39.
In the last 3 years, TEVA traded as high as $40.79 and as low as $8.06.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): IEFA, EFA, EIS, WCMI, EFG.
TEVA has outperformed the market in the last year with a return of +95.6%, while the SPY ETF gained +17.7%. In the last 3 month period, TEVA beat the market returning +13.0%, while SPY returned +5.0%. However, in the most recent 2 weeks TEVA has underperformed the stock market by returning -2.3%, while SPY returned +0.9%.
TEVA support price is $38.81 and resistance is $40.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA shares will trade within this expected range on the day.